Release Details

SOUTH PLAINFIELD, N.J., Feb. 12, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the second annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne muscular dystrophy (DMD). STRIVE provides funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates.

"February is an important month for the rare disease community as we work to generate awareness for rare diseases internationally," said Mary Frances Harmon, Global Head of Patient Advocacy at PTC. "PTC has been dedicated to the development of treatments for rare and neglected diseases for the last 18 years, and patient advocacy groups have been critical to this mission. With the STRIVE program, we are enabling these organizations to develop new strategies for improving the lives of patients and families dealing with DMD, and, after the success of the program last year, we are excited to see what creative ideas are proposed in 2016."

The program is aimed at improving the diagnosis and treatment of DMD patients, increasing the visibility of this devastating rare disorder and educating the general public and healthcare professionals, as well as identifying and fostering the next generation of DMD patient advocates. One-year awards of up to $30,000 will be given to the most creative, feasible and sustainable proposals identified by a panel of judges. The deadline for submission of proposals is May 31, 2016, and awards will be announced on World Duchenne Awareness Day, on Sept. 7.

For more information and to apply, please visit the STRIVE Awards Program's website at: www.ptcbio.com/en/strive.

About PTC Therapeutics

PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA, or mRNA, molecule is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com

For More Information:

Investors:
Emily Hill
+1 (908) 912-9327
ehill@ptcbio.com

Media:
Justine O'Malley
+1 (908) 912-9551
jomalley@ptcbio.com

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements, other than those of historical fact contained in this release are forward-looking statements, including statements regarding the future expectations, plans and prospects for PTC. Other forward-looking statements may be identified by the words "plan," "guidance," "anticipate," "believe," "estimate," "expect," "intend," "may," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this release except as required by law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-second-annual-strive-grant-award-program-for-duchenne-muscular-dystrophy-300219107.html

SOURCE PTC Therapeutics, Inc.